ArticleJournal of translational medicine2026
First-in-human PET study of [
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHistone deacetylase 6 (HDAC6) is a lysine deacetylase that modulates protein function and turnover, and is critically implicated in the pathogenesis of neurodegenerative disorders. [
methodsIn cohort A, whole-body PET was performed in three healthy men to evaluate radiation dosimetry, with serial imaging conducted from 1 min to 2 h after injection followed by additional scans at 4 h and 6 h. Absorbed doses in individual organs and the effective dose were estimated. In cohort B, five healthy men underwent 120-min dynamic brain PET with arterial blood sampling for radioactivity measurement and metabolite analysis. To determine optimal kinetic modeling, one- and two-tissue compartment models (1-TCM and 2-TCM), along with Logan graphical analysis (LGA), were applied to estimate distribution volume (V
resultsThe scan protocol was well tolerated by all subjects. In cohort A, effective dose was estimated at 18.9 ± 1.7 µSv/MBq, with the highest absorbed dose observed in the gallbladder wall (379 ± 136 µGy/MBq). Accordingly, as a precaution to minimize gallbladder dose, cohort B received a lower administered radioactivity. In brain PET analysis, 2-TCM better described radioligand kinetics than 1-TCM. V
conclusions[
trial registrationJapan Registry of Clinical Trials (jRCT), jRCTs031240173. Registered 19 June 2024, https://jrct.mhlw.go.jp/latest-detail/jRCTs031240173 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.